Skip to main content
. Author manuscript; available in PMC: 2020 Nov 1.
Published in final edited form as: Hepatology. 2019 Jun 18;70(5):1531–1545. doi: 10.1002/hep.30674

Table 4b.

Changes in whole body fat depots and muscle volume by MRI in Aramchol- Versus Placebo-Treated Patients

Aramchol (n=19) Placebo (n=20) Difference
Baseline Posttreatment P-Value Baseline Posttreatment P-Value P-Value
 VAT (l) 6.1 (2.8) 5.6 (3.0) 0.5533 6.7 (2.7) 6.4 (2.3) 0.6280 0.6118
 ASAT (l) 7.9 (4.7) 8.2 (5.9) 0.9530 8.1 (4.3) 8.1 (3.9) 0.6507 0.4959
 VAT + ASAT (l) 14.6 (4.3) 14.3 (4.9) 0.9323 14.9 (4.2) 15.3 (4.1) 0.7906 0.4634
 Visceral fat ratio (%) 42.1 (18.9) 40.9 (13.5) 0.9323 44.1 (15.6) 44.0 (15.5) 0.5678 0.9403
 Thigh volume (l) 12.6 (1.8) 12.5 (1.5) 0.4037 11.8 (2.9) 11.7 (2.9) 0.8063 0.4447
 Muscle ratio (kg/l) 7.2 (1.2) 7.1 (1.1) 0.3894 7.7 (2.3) 7.7 (1.9) 0.8176 0.3661
 Fat storage (l/m2) 5.0 (1.3) 5.0 (1.6) 0.8900 5.0 (1.8) 5.0 (1.2) 0.3529 0.8737
 Visceral Fat Index (l/m2) 2.0 (0.7) 1.9 (0.9) 0.6685 2.3 (0.6) 2.1 (0.6) 0.2121 0.7221
 Fat ratio (%) 53.2 (7.3) 52.9 (8.1) 0.8904 54.4 (11.9) 55.0 (9.5) 0.9661 0.3584
Pericardial Volume (mm3) 183300 (103100) 202800 (75900) 0.2500 136500 (72019) 171050 (176500) 0.0134 0.1633

Data are expressed as median (IQR) with p-values from Wilcoxon signed rank test or mean difference with P-value from t-test in parentheses. N’s are “best case” P-values in bold denote statistical significance < 0.05.